CSS
STLN

Cubist Systematic Strategies’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Cubist Systematic Strategies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$646K Buy
185,160
+150,463
+434% +$516K ﹤0.01% 2161
2025
Q2 		$71.1K Buy
+34,697
New +$86.7K ﹤0.01% 2747
2024
Q1 		– Sell
-12,320
Closed -$25.1K – 4276
2023
Q4 		$25.1K Buy
+12,320
New +$21.4K ﹤0.01% 3330
2023
Q3 		– Sell
-35,621
Closed -$19.6K – 3914
2023
Q2 		$19.6K Buy
+35,621
New +$18.8K ﹤0.01% 3185

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cubist Systematic Strategies's STLN Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 434% in Q3 2025, buying an estimated $516K and bringing the position to 185,160 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Cubist Systematic Strategies first reported a position in STLN in Q2 2023 and has held it in 4 quarters since. 108 funds tracked by Wall St. Rank hold STLN as of Q3 2025.

  • Cubist Systematic Strategies held 185,160 shares of Starling Oncology Institute, Inc. Common Stock worth $646K as of Q3 2025.
  • Cubist Systematic Strategies bought 150,463 Starling Oncology Institute, Inc. Common Stock shares in Q3 2025, an estimated $516K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2161 holding.
  • Cubist Systematic Strategies first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2023 and has held it in 4 quarters since.
  • 108 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.